Format

Send to

Choose Destination
See comment in PubMed Commons below
Virol J. 2013 Oct 5;10:301. doi: 10.1186/1743-422X-10-301.

A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of hantaan virus induced protective immunity in mice.

Author information

1
Department of Microbiology, Fourth Military Medical University, Xi'an, 710032, China. flzhang@fmmu.edu.cn.

Abstract

BACKGROUND:

Hantaviruses cause acute hemorrhagic fever with renal syndrome (HFRS). Currently, several types of inactivated HFRS vaccines are widely used, however the limited ability of these immunogen to elicit neutralizing antibodies restricts vaccine efficacy. Development of an effective vaccine to overcome this weakness is must.

METHODS:

In the present study, a recombinant pseudotyped lentivirus bearing the hantaan virus (HTNV) envelope glycoproteins (GP), rLV-M, was constructed. C57BL/6 mice were immunized with the rLV-M and a series of immunological assays were conducted to determine the immunogenicity of the recombinant pseudotyped lentivirus. The humoral and cell-mediated immune responses induced by rLV-M were compared with those of the inactivated HFRS vaccine.

RESULTS:

Indirect immunofluorescence assay (IFA) showed the rLV-M expressed target proteins in HEK-293 cells. In mice, the rLV-M efficiently induced GP-specific humoral responses and protection against HTNV infection. Furthermore, the rLV-M induced higher neutralizing antibody titers than the inactivated HFRS vaccine control.

CONCLUSIONS:

The results indicated the potential of using a pseudotyped lentivirus as a delivery vector for a hantavirus vaccine immunogen.

PMID:
24093752
PMCID:
PMC3851560
DOI:
10.1186/1743-422X-10-301
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center